{"id":45747,"date":"2025-11-04T20:59:19","date_gmt":"2025-11-04T12:59:19","guid":{"rendered":"https:\/\/flcube.com\/?p=45747"},"modified":"2025-11-04T20:59:21","modified_gmt":"2025-11-04T12:59:21","slug":"genans-biotechnology-receives-fda-fast%e2%80%91track-designation-for-ga001-injection-a-promising-gene%e2%80%91therapy-for-retinitis-pigmentosa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45747","title":{"rendered":"GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa"},"content":{"rendered":"\n<p>China\u2011based <strong>GenAns Biotechnology Co., Ltd.<\/strong> announced that its proprietary gene\u2011therapy drug <strong>GA001 injection<\/strong> received <strong>Fast\u2011Track Designation (FTD)<\/strong> from the United States Food and Drug Administration (FDA) for treating advanced blindness caused by <strong>Retinitis Pigmentosa (RP)<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-what-is-ga001-injection\">What is GA001 Injection?<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Technology Platform<\/strong> \u2013 A highly sensitive, novel photosensitive protein encoded by a custom-designed gene.<\/li>\n\n\n\n<li><strong>Delivery Vehicle<\/strong> \u2013 Adeno\u2011associated virus (AAV) vector engineered to target retinal ganglion cells directly.<\/li>\n\n\n\n<li><strong>Mechanism of Action<\/strong> \u2013 The delivered gene restores light\u2011sensing function in retinal ganglion cells, enabling the recovery of visual perception.<\/li>\n\n\n\n<li><strong>Clinical Milestones<\/strong> \u2013 FDA approval to advance to Phase\u202fII trials in the United States, with a projected enrollment of approximately 200 RP patients.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-fast-track-designation-why-it-matters\">Fast\u2011Track Designation: Why It Matters<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Benefit<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Accelerated development<\/strong><\/td><td>Shortened review timelines, priority review, and potential for accelerated approval.<\/td><td>Faster access for patients who currently have limited therapeutic options.<\/td><\/tr><tr><td><strong>Reduced bureaucratic burden<\/strong><\/td><td>Reduced information requirements at interim milestones.<\/td><td>Lower cost and time to market compared to non\u2011designated pathways.<\/td><\/tr><tr><td><strong>Enhanced transparency<\/strong><\/td><td>Real\u2011time FDA\u2011GenAns consultations.<\/td><td>Opportunity to integrate adaptive trial designs and early patient\u2011feedback loops.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>Fast\u2011Track status signals that the FDA considers GA001 injection to be a <strong>potential breakthrough therapy<\/strong>, underscoring its <strong>innovative vector design<\/strong> and the urgent unmet need in the RP community.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-market-landscape-amp-competitive-context\">Market Landscape &amp; Competitive Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global RP Pipeline<\/strong> \u2013 Currently dominated by AAV\u2011based therapies from U.S. firms such as <strong>BioTechne<\/strong> and <strong>Viral Therapeutics<\/strong>, GenAns now stands with a first\u2011in\u2011China, independently engineered protein.<\/li>\n\n\n\n<li><strong>Commercial Potential<\/strong> \u2013 RP is an orphan disease affecting ~1 in 4,000 people worldwide; successful clinical proof\u2011of\u2011concept could open a multi\u2011million\u2011dollar market for sight\u2011restoring treatments.<\/li>\n\n\n\n<li><strong>Strategic Partnerships<\/strong> \u2013 GenAns is actively courting U.S. co\u2011development partners; Fast\u2011Track status enhances partnership attractiveness and may expedite funding rounds.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-takeaways\">Key Takeaways<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Regulatory Milestone<\/strong> \u2013 FDA Fast\u2011Track paves the way for quicker market access.<\/li>\n\n\n\n<li><strong>Technical Innovation<\/strong> \u2013 Novel photosensitive protein delivered via AAV offers a unique therapeutic angle.<\/li>\n\n\n\n<li><strong>Future Outlook<\/strong> \u2013 Phase\u202fII data could be the linchpin for positioning GA001 as the first commercially available gene\u2011therapy to restore vision in advanced RP patients.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based GenAns Biotechnology Co., Ltd. announced that its proprietary gene\u2011therapy drug GA001 injection received Fast\u2011Track&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45749,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4426,66,44],"class_list":["post-45747","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-genans-biotechnology","tag-gene-therapy","tag-ophthalmology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based GenAns Biotechnology Co., Ltd. announced that its proprietary gene\u2011therapy drug GA001 injection received Fast\u2011Track Designation (FTD) from the United States Food and Drug Administration (FDA) for treating advanced blindness caused by Retinitis Pigmentosa (RP).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45747\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa\" \/>\n<meta property=\"og:description\" content=\"China\u2011based GenAns Biotechnology Co., Ltd. announced that its proprietary gene\u2011therapy drug GA001 injection received Fast\u2011Track Designation (FTD) from the United States Food and Drug Administration (FDA) for treating advanced blindness caused by Retinitis Pigmentosa (RP).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45747\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T12:59:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-04T12:59:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0404.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45747#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45747\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa\",\"datePublished\":\"2025-11-04T12:59:19+00:00\",\"dateModified\":\"2025-11-04T12:59:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45747\"},\"wordCount\":368,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45747#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0404.webp\",\"keywords\":[\"GenAns Biotechnology\",\"Gene therapy\",\"Ophthalmology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45747#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45747\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45747\",\"name\":\"GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45747#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45747#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0404.webp\",\"datePublished\":\"2025-11-04T12:59:19+00:00\",\"dateModified\":\"2025-11-04T12:59:21+00:00\",\"description\":\"China\u2011based GenAns Biotechnology Co., Ltd. announced that its proprietary gene\u2011therapy drug GA001 injection received Fast\u2011Track Designation (FTD) from the United States Food and Drug Administration (FDA) for treating advanced blindness caused by Retinitis Pigmentosa (RP).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45747#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45747\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45747#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0404.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/0404.webp\",\"width\":1080,\"height\":608,\"caption\":\"GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45747#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based GenAns Biotechnology Co., Ltd. announced that its proprietary gene\u2011therapy drug GA001 injection received Fast\u2011Track Designation (FTD) from the United States Food and Drug Administration (FDA) for treating advanced blindness caused by Retinitis Pigmentosa (RP).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45747","og_locale":"en_US","og_type":"article","og_title":"GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa","og_description":"China\u2011based GenAns Biotechnology Co., Ltd. announced that its proprietary gene\u2011therapy drug GA001 injection received Fast\u2011Track Designation (FTD) from the United States Food and Drug Administration (FDA) for treating advanced blindness caused by Retinitis Pigmentosa (RP).","og_url":"https:\/\/flcube.com\/?p=45747","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-04T12:59:19+00:00","article_modified_time":"2025-11-04T12:59:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0404.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45747#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45747"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa","datePublished":"2025-11-04T12:59:19+00:00","dateModified":"2025-11-04T12:59:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45747"},"wordCount":368,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45747#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0404.webp","keywords":["GenAns Biotechnology","Gene therapy","Ophthalmology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45747#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45747","url":"https:\/\/flcube.com\/?p=45747","name":"GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45747#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45747#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0404.webp","datePublished":"2025-11-04T12:59:19+00:00","dateModified":"2025-11-04T12:59:21+00:00","description":"China\u2011based GenAns Biotechnology Co., Ltd. announced that its proprietary gene\u2011therapy drug GA001 injection received Fast\u2011Track Designation (FTD) from the United States Food and Drug Administration (FDA) for treating advanced blindness caused by Retinitis Pigmentosa (RP).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45747#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45747"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45747#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0404.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0404.webp","width":1080,"height":608,"caption":"GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45747#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GenAns Biotechnology Receives FDA Fast\u2011Track Designation for GA001 Injection, a Promising Gene\u2011Therapy for Retinitis Pigmentosa"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/0404.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45747","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45747"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45747\/revisions"}],"predecessor-version":[{"id":45750,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45747\/revisions\/45750"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45749"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45747"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45747"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45747"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}